Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Promotes anchorage-independent cell growth and tumor formation (By similarity). Additionally we are shipping KIAA1524 Kits (7) and KIAA1524 Proteins (4) and many more products for this protein.
Showing 10 out of 66 products:
Human Monoclonal KIAA1524 Primary Antibody for FACS, ICC - ABIN258615
Soo Hoo, Zhang, Chan: Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. in Oncogene 2002
Show all 10 Pubmed References
Human Polyclonal KIAA1524 Primary Antibody for ICC, IF - ABIN261179
Pallai, Bhaskar, Sodi, Rice: Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. in Transcription 2013
Show all 9 Pubmed References
Human Polyclonal KIAA1524 Primary Antibody for FACS, ICC - ABIN261740
Kerosuo, Fox, Perälä, Ahlqvist, Suomalainen, Westermarck, Sariola, Wartiovaara: CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. in Differentiation; research in biological diversity 2010
Show all 8 Pubmed References
Membranous CIP2A expression as a potential novel prognostic and predictive indicator for tamoxifen resistance.
Cip2a effectively promotes triple-negative breast cancer (TNBC) cell cycle progression and tumor growth via regulation of PP2A (show PPP2R4 Antibodies)/c-myc (show MYC Antibodies)/p27Kip1 (show CDKN1B Antibodies) signaling, which could serve as a potential therapeutic target for TNBC patients.
poor prognosis of chronic myeloid leukemia (show BCL11A Antibodies) patients with high CIP2A levels is due to an antiapoptotic phenotype
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A (show PPP2R4 Antibodies)/B56
CIP2A is upregulated in MM, and CIP2A expression promotes cell proliferation and clonogenic formation ability by regulating the expression of AKT (show AKT1 Antibodies) phosphorylation and c-Myc (show MYC Antibodies).
Gambogenic acid is a CIP2A inhibitor that interferes with the ubiquitination and destabilization of CIP2A.
Silencing CIP2A enhanced CuB-induced growth inhibition.
CIP2A copy number increase is associated with poor patient survival in human HNSCC.
These results indicate that CIP2A modulates myeloma cell proliferation and apoptosis via PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies)/mTOR (show FRAP1 Antibodies) signaling and suggest that it can potentially serve as a drug target for the treatment of multiple myeloma.
CIP2A is involved in regulating multidrug resistance of cervical adenocarcinoma.
Knockdown of CIP2A by stable CIP2A siRNA transfection inhibited MDA-MB-231 cell proliferation, invasion, colony growth in vitro, and xenograft growth and metastasis in vivo of breast cancer in mice.
CIP2A as a hitherto unrecognized mediator of T-cell activation.
Downregulation of CIP2A suppresses cell proliferation and growth of nasopharyngeal carcinoma.
CIP2A strongly interacts with NEK2 (show NEK2 Antibodies) during G2/M phase, thereby enhancing NEK2 kinase (show NEK2 Antibodies) activity to facilitate centrosome separation in a PP1 (show PPP1CC Antibodies)- and PP2A (show PPP2R2B Antibodies)-independent manner.
Data show that CIP2A expression can be systematically inhibited without severe consequences to normal mouse development and viability may have clinical relevance regarding targeting of oncogenic CIP2A for future cancer therapies.
Loss of CIP2A in Myc (show MYC Antibodies)-overexpressing neural progenitor cells significantly reduces the ability of Myc (show MYC Antibodies) to increase self-renewal and proliferation.
Promotes anchorage-independent cell growth and tumor formation (By similarity).
protein CIP2A homolog
, CONSTANS interacting protein 2a
, hypothetical protein LOC100216050
, cancerous inhibitor of PP2A
, p90 autoantigen
, protein CIP2A
, p90 autoantigen homolog